TCRCure Biopharma Ltd.aims to develop next generation cancer immunotherapies that control tumor progression, convert cancers to manageable chronic diseases, and eventually lead toacure. TCRCure is a leading international company focusedon streamlined biotechnology development including high throughput antigen-specific TCR cloning, industry scale virus production, T cellgenetic engineering,and immune cell manufacturing.
TCRCure has established two GMP-level manufacturing facilitiesin Los Angeles and Guangzhou, as well as two translational medicine centers in North Carolina and Chongqing.
As of 2018, TCRCure has over 70 employees, with more than 40% of thembeing Ph.Ds. The companyhas several pipelines of TCR-T cell therapy products for solid tumors including cervical cancer, nasopharyngeal carcinoma，head and neck cancer，lung squamous carcinoma, colorectal cancer, ovarian cancer, multiple myeloma, and braincancer. TCRCure has started clinical trials and translational medicine research in coordination with thetop hospitals in Chongqing, Chengdu, and Guangzhou,China.
In addition, TCRCure has solid clinical data and robust pipelines for viral vector and T cell manufacturing. The company has obtained technology authorization, commissioned R&D contracts, received production orders from pharmaceutical factories, and has attracted millions of USD in funding from top investment companies.